Key result
DOACs show no difference versus standard therapy for VTE recurrence and bleeding in cancer patients.
Why the study?
Patients with cancer have an elevated risk of VTE, and while LMWH and warfarin are standard therapies, DOACs are increasingly used, requiring comparative safety and efficacy assessment.
Do direct oral anticoagulants reduce VTE recurrence compared to standard therapy (LMWH and warfarin) in patients with cancer-associated VTE?
Meta-Analysis (n=3,325)
Do direct oral anticoagulants reduce VTE recurrence compared to standard therapy (LMWH and warfarin) in patients with cancer-associated VTE?
A network meta-analysis found no statistically significant differences in efficacy or safety between DOACs, LMWH, and warfarin for cancer-associated VTE, though wide credible intervals limit precision.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Comparable VTE outcomes with DOACs versus standard therapy in cancer; wide credible intervals leave optimal agent selection open.
Background: Patients with malignancy demonstrate an elevated risk of developing venous thromboembolism (VTE) due to coagulopathy and treatment modalities. Although low-molecular-weight heparin (LMWH) and warfarin have historically been standard therapies, direct oral anticoagulants (DOACs) are increasingly used in this population. Methods: We conducted a Bayesian network meta-analysis to compare the safety and efficacy of apixaban, edoxaban, rivaroxaban, LMWH, and warfarin in cancer-associated VTE. A comprehensive literature search of Embase, Medline, clinical trial registries, and manual sources was performed up to November 2025. The primary outcome was to compare the risk of VTE recurrence across therapies. Secondary outcomes included major bleeding, clinically relevant non-major bleeding (CRNMB), and all-cause mortality. Odds ratios (ORs) with 95% credible intervals (CrIs) were estimated, and treatment rankings were derived using the surface under the cumulative ranking curves (SUCRA) probabilities. Results: Seven randomized controlled trials (RCTs) involving 3325 patients were included. No clear evidence of differences was observed among apixaban, rivaroxaban, edoxaban, low-molecular-weight heparin, and warfarin for VTE recurrence, major bleeding, clinically relevant non-major bleeding, and mortality. For instance, rivaroxaban showed no statistically significant difference in VTE recurrence compared with apixaban (OR 1.13; 95% CrI 0.17–12.27), warfarin (OR 0.60; 95% CrI 0.03–19.00), edoxaban (OR 0.77; 95% CrI 0.06–11.11), or LMWH (OR 0.51; 95% CrI 0.10–2.66). Wide credible intervals reflect uncertainty due to the limited number of RCTs and low event rates. Conclusions: This Bayesian network meta-analysis showed no statistically significant differences between therapies with respect to VTE recurrence, bleeding outcomes, and mortality. However, the wide credible intervals indicate limited precision, warranting cautious interpretation of the findings.
Shahbar et al. (2026) conducted a meta-analysis in Cancer-associated venous thromboembolism (n=3,325). Direct oral anticoagulants (apixaban, edoxaban, rivaroxaban) vs. Standard therapy (low-molecular-weight heparin and warfarin) was evaluated on VTE recurrence (OR 0.51, 95% CI 0.10-2.66). Direct oral anticoagulants showed no significant difference in VTE recurrence compared to standard therapy in cancer patients.
Synapse has enriched 10 related papers. Consider them for comparative context: